ArticleMaterials today. Bio2025
Injectable tert-butylphenylacetic acid/acrylated β-cyclodextrin-based hydrogels for co-delivery of CAR-T cells and IL-15 in solid tumor therapy.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cell-Type-Tailored Hydrogels for Adoptive Cell Therapy in Cancer.Gels (Basel, Switzerland) · 2026Review
- Bridging biomaterials and immunotherapy: hydrogel strategies for next-generation CAR-T cell treatment.Stem cell research & therapy · 2026Review
- Self-passivated bilayer black phosphorus QDs based multifunctional nanoparticles for tumor immune reprogramming.Materials today. Bio · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chimeric antigen receptor (CAR)-T cell therapy has shown great potential in treating hematologic malignancies, but its efficacy in solid tumors is limited by the immunosuppressive microenvironment and poor tumor infiltration. Hydrogels possess excellent local delivery capabilities, providing a supporting environment for adoptive cells and enhancing their tumor retention. Here, we report injectable supramolecular hydrogels composed of hyaluronic acid grafted with tert-butylphenylacetic acid (HA-TP) and acrylated β-cyclodextrin (AC-β-CD) for the co-delivery of CAR-T cells and IL-15. The hydrogels rapidly form a stable 3D network via host-guest interactions and acrylate photocrosslinking, providing a niche that retains and activates CAR-T cells. Interleukin (IL)-15 promotes CAR-T cell proliferation, leading to improved infiltration and antitumor cytotoxicity. In mouse models of B16-F10-ovalbumin (OVA) melanoma and B cell lymphoma, the hydrogels mediate the extensive infiltration of OVA-specific CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.